AtriCure Inc (Nasdaq:ATRC) on Tuesday reported the completion of the acquisition of SentreHEART Inc for an undisclosed amount.
Based in Redwood City, California, SentreHEART is a privately-owned medical device company committed to clinical evidence development and is currently sponsoring the FDA-approved prospective, multi-centre, randomized controlled trial (aMAZE Trial).
Founded in 2005, SentreHEART has developed innovative technology for remote delivery of suture for closure of anatomic structures including the left atrial appendage (LAA).
According to AtriCure Inc, it provides innovative technologies for the treatment of Afib and related conditions. The electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications.
Krystal Biotech receives FDA approval for updated VYJUVEK label
Renalytix signs collaboration agreement with Tempus AI to expand KidneyIntelX.dkd access
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Implantica produces 10,000 RefluxStop units ahead of planned US launch
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA